

Exhibit F

1
2 IN THE UNITED STATES DISTRICT COURT
3 FOR THE SOUTHERN DISTRICT OF NEW YORK
4

5 UMB BANK, N.A., as Trustee,)
6)
7 Plaintiff,) No. 1:15-CV-08725
8) (GBD) (RWL)
9 vs.)
10)
11 SANOFI,)
12)
13 Defendant.)
14 -----)

15 VIDEOTAPED DEPOSITION OF MANFRED CAESER
16 New York, New York
17 Thursday, March 14, 2019
18
19
20
21
22

23 Reported by:
24 KRISTIN KOCH, RPR, RMR, CRR
25 JOB NO. 156492

1 M. Caesar

2 referring to major markets ex-U.S.; correct?

3 A. Yes.

4 Q. Okay. So can we just have an
5 understanding amongst all of us that if we
6 refer to major markets today, whether it's
7 yourself or myself, that we are excluding the
8 U.S. from that?

9 A. Yes.

10 MR. MINTZ: No objection.

11 Q. And your report doesn't contain any
12 calculations of Sanofi's Lemtrada sales in the
13 major markets, does it?

14 A. Say it again, please.

15 MR. MINTZ: Objection to form.

16 Q. Did you perform your own
17 calculations of Lemtrada sales?

18 A. On my own calculation, no.

19 Q. In the major markets.

20 A. I did not do any calculations on my
21 own. I am completely relying on the evidence
22 that was produced by Sanofi in the critical
23 time period.

24 Q. So you have not performed a
25 calculation of sales of Lemtrada that would

1 M. Caesar
2 have occurred had Sanofi commercialized
3 Lemtrada in a different manner; correct?

4 A. That's not my task.

5 Q. Okay. Do you intend to do that?

6 A. No.

7 Q. Do you intend to offer any damages
8 testimony with respect to Sanofi's
9 commercialization of Lemtrada in the major
10 markets?

11 MR. MINTZ: Objection to form.
12 Vague.

13 A. I completely don't understand your
14 question. What do you mean by --

15 Q. Do you intend to provide any
16 calculations with respect to sales of Lemtrada
17 in the major markets?

18 MR. MINTZ: Objection to form.

19 A. No, I'm not supposed to provide my
20 own calculations. As -- as the task is defined
21 right now, there is no basis for calculations.

22 Q. Paragraphs 167 to 171 of your
23 report --

24 A. Paragraph 67 --

25 Q. 167.